1.11
-0.02(-1.77%)
Currency In USD
| Previous Close | 1.13 |
| Open | 1.13 |
| Day High | 1.15 |
| Day Low | 1.08 |
| 52-Week High | 4.85 |
| 52-Week Low | 0.91 |
| Volume | 4.59M |
| Average Volume | 4.8M |
| Market Cap | 158.53M |
| PE | -4.11 |
| EPS | -0.27 |
| Moving Average 50 Days | 1.23 |
| Moving Average 200 Days | 1.74 |
| Change | -0.02 |
If you invested $1000 in Humacyte, Inc. (HUMA) since IPO date, it would be worth $114.79 as of January 14, 2026 at a share price of $1.11. Whereas If you bought $1000 worth of Humacyte, Inc. (HUMA) shares 5 years ago, it would be worth $108.93 as of January 14, 2026 at a share price of $1.11.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications
GlobeNewswire Inc.
Jan 08, 2026 1:00 PM GMT
- Data is from comprehensive review of hospital charges and all-payer claims over five years - - Preventable complications such as amputation and conduit infection increased initial hospital charges by approximately $493,000 and $590,000 per patient
Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel
GlobeNewswire Inc.
Jan 05, 2026 1:00 PM GMT
- Expansion plans are based on requests for product access received from surgeons and hospitals in Israel - - Expansion of Symvess into other territories, including those in Europe and the Middle East, is also planned - DURHAM, N.C., Jan. 05, 2026
Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair
GlobeNewswire Inc.
Dec 22, 2025 1:00 PM GMT
- Results published in Journal of Vascular Surgery Cases, Innovations and Techniques (JVS-CIT) - - After up to 36 months of follow-up, patients demonstrated high limb salvage, low rates of infection, no unprovoked structural failures - - Results re